Letters Insulin manufacture

Marketing insulins

BMJ 2011; 342 doi: http://dx.doi.org/10.1136/bmj.d471 (Published 25 January 2011) Cite this as: BMJ 2011;342:d471
  1. Robert Tattersall, retired professor of clinical diabetes1
  1. 1Sheffield S11 7EJ, UK
  1. robert.tattersall021{at}gmail.com

Cohen and Carter point out the lack of evidence that analogues are better than human insulin and conclude that marketing accounts for their success.1 We have been here before.

In the 1970s, human insulin was thought in some unspecified way to be better than animal insulin, and Novo and Eli Lilly started a race to make and …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe